StockData
ADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA) stock

ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3027% below fair value
$13.56−0.07 (-0.51%)

Close on Nov 18, 2026Market cap $3.04BP/E 19.4Yield –

ADMA Biologics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ADMA Biologics's free cash flow for the twelve months ending Jun 30, 2026 was $116.47M, up 77.1% year over year. For fiscal 2025 it was $27.82M, down 74.8% from the year before. The highest annual figure on record is $110.45M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$27.82M-74.8%
FY2024Dec 31, 2024$110.45M+2641.3%
FY2023Dec 31, 2023$4.03M–
FY2022Dec 31, 2022-$73.42M–
FY2021Dec 31, 2021-$125.88M–
FY2020Dec 31, 2020-$114.73M–
FY2019Dec 31, 2019-$80.01M–
FY2018Dec 31, 2018-$64.77M–
FY2017Dec 31, 2017-$39.95M–
FY2016Dec 31, 2016-$18.34M–
FY2015Dec 31, 2015-$15.44M–
FY2014Dec 31, 2014-$17.03M–
FY2013Dec 31, 2013-$11.08M–
FY2012Dec 31, 2012-$7.02M–
FY2011Dec 31, 2011-$1.43M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$27.28M+45.8%
Q1 FY2026Mar 31, 2026$55.71M–
Q4 FY2025Dec 31, 2025$34.56M-27.2%
Q3 FY2025Sep 30, 2025-$1.08M-104.5%
Q2 FY2025Jun 30, 2025$18.72M-57.1%
Q1 FY2025Mar 31, 2025-$24.38M–
Q4 FY2024Dec 31, 2024$47.46M+189.4%
Q3 FY2024Sep 30, 2024$23.97M+113.5%
Q2 FY2024Jun 30, 2024$43.58M–
Q1 FY2024Mar 31, 2024-$4.57M–
Q4 FY2023Dec 31, 2023$16.40M–
Q3 FY2023Sep 30, 2023$11.23M–
Q2 FY2023Jun 30, 2023-$6.93M–
Q1 FY2023Mar 31, 2023-$16.67M–
Q4 FY2022Dec 31, 2022-$11.13M–
Q3 FY2022Sep 30, 2022-$16.67M–
Q2 FY2022Jun 30, 2022-$16.77M–
Q1 FY2022Mar 31, 2022-$28.86M–
Q4 FY2021Dec 31, 2021-$37.14M–
Q3 FY2021Sep 30, 2021-$16.20M–
Q2 FY2021Jun 30, 2021-$36.74M–
Q1 FY2021Mar 31, 2021-$35.80M–
Q4 FY2020Dec 31, 2020-$35.82M–
Q3 FY2020Sep 30, 2020-$26.74M–
Q2 FY2020Jun 30, 2020-$25.45M–
Q1 FY2020Mar 31, 2020-$26.72M–
Q4 FY2019Dec 31, 2019-$21.25M–
Q3 FY2019Sep 30, 2019-$26.09M–
Q2 FY2019Jun 30, 2019-$18.27M–
Q1 FY2019Mar 31, 2019-$14.40M–
Q4 FY2018Dec 31, 2018-$19.61M–
Q3 FY2018Sep 30, 2018-$12.77M–
Q2 FY2018Jun 30, 2018-$15.41M–
Q1 FY2018Mar 31, 2018-$16.98M–
Q4 FY2017Dec 31, 2017-$15.37M–
Q3 FY2017Sep 30, 2017-$10.31M–
Q2 FY2017Jun 30, 2017-$8.87M–
Q1 FY2017Mar 31, 2017-$5.40M–
Q4 FY2016Dec 31, 2016-$3.62M–
Q3 FY2016Sep 30, 2016-$4.69M–

More ADMA Biologics figures

See a number that looks wrong?